Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. Recommendations on the use of 18F-FDG PET in oncology 3. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials 4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer 5. Sentinel node biopsy is important in mastectomy for ductal carcinoma in situ
Top Ten Searches
brca1 prostate-specific antigen sclc fobt egd bmi dysplasia hematologic ovarian hccYour Article Summary
See Latest ArticlesCardiotoxicity induced by tyrosine kinase inhibitors
Acta Oncologica, 09/21/09
Orphanos GS et al. – Cardiotoxicity is a serious side effect of drugs used to treat cancer patients. Older chemotherapy drugs such as the anthracyclins and new targeted therapies, mainly trastuzumab, have been implicated in causing clinically significant cardiac dysfunction, which may be irreversible for many patients. The advent of a new category of drugs, the tyrosine kinase inhibitors has revolutionized the treatment of chronic myeloid leukemia, gastrointestinal stromal tumors and renal cancer, while their indications include a variety of other types of tumors. Careful cardiac monitoring and assessment by a cardiologist throughout the course of treatment with those TKIs that exert cardiac toxic effect is of primary importance.
Related Articles
Chronic doxorubicin cardiotoxicity is mediated by oxidative DNA damage-ATM-p53-apoptosis pathway and attenuated by pitavastatin through the inhibition of Rac1 activity
Journal of Molecular and Cellular Cardiology, 10/20/09
Relevance Score: 84%
The art of healing broken hearts in breast cancer patients: Trastuzumab and heart failure
Experimental and Clinical Cardiology, 11/16/09
Relevance Score: 82%
Phase II multicenter trial of anthracycline rechallenge with pegylated liposomal doxorubicin plus cyclophosphamide for first-line therapy of metastatic breast cancer previously treated with adjuvant anthracyclines
Journal of Clinical Oncology, 10/30/09
Relevance Score: 80%
Liposomes and nanoparticles: nanosized vehicles for drug delivery in cancer
Trends in Pharmacological Sciences, 10/29/09
Relevance Score: 80%
Sub-lethal doses of an anti-erbB2 antibody leads to death by apoptosis in cardiomyocytes sensitized by low pro-senescent doses of epirubicin: the protective role of dexrazoxane
Journal of Pharmacology and Experimental Therapeutics, 10/26/09
Relevance Score: 80%
Today in Pharmacology/Therapy...keeping you current
Receive free subspecialty "5-minute updates" via email
ETAR antagonist ZD4054 exhibits additive effects with aromatase inhibitors and fulvestrant in breast cancer therapy, and improves in vivo efficacy of anastrozole
Breast Cancer Research and Treatment, 12/02/09
A novel synthetic iminoquinone, BA-TPQ, as an anti-breast cancer agent: in vitro and in vivo activity and mechanisms of action
Breast Cancer Research and Treatment, 12/02/09
FDA Drug Approval Summary: Bevacizumab (Avastin) as Treatment of Recurrent Glioblastoma Multiforme
The Oncologist, 12/02/09
Today in Side Effects...keeping you current
Receive free subspecialty "5-minute updates" via email
Bisphosphonates and Time to Osteonecrosis Development
The Oncologist, 12/02/09
Hepatic Toxicities Associated with the Use of Preoperative Systemic Therapy in Patients with Metastatic Colorectal Adenocarcinoma to the Liver
The Oncologist, 12/02/09
Incidence of oral mucositis, its treatment and pain management in patients receiving cancer treatment at Radiation Oncology Departments in Spanish hospitals (MUCODOL Study)
Clinical and Translational Oncology, 11/25/09
Sponsor
Article Search
Sponsor
Sponsor